MAPK3 and colorectal carcinoma: Of note, siRNA-mediated knockdown of ERK1/2 and/or ERK5 validated these MAPKs as drug targets in CRC, although cell lines were relatively more susceptible to ERK1/2 knockdown (Supplementary Fig. 7e,f).